From day one, President Trump has made it clear that lowering prescription drug costs is a top priority. In May, the President released his drug-pricing blueprint, which includes the most sweeping set of policies to lower drug prices ever put forth by an administration. HHS has been hard at work to make the President’s vision a reality – because the status quo is simply unacceptable.
Over the past year, the Centers for Medicare & Medicaid Services (CMS) has engaged with the provider community in a discussion about regulatory burden issues. This included publishing a Request for Information (RFI) soliciting comments about areas of high regulatory burden.
91 percent of all clinicians eligible for the Merit-based Incentive Payment System (MIPS) participated in the first year of the Quality Payment Program (QPP). The submission rates for Accountable Care Organizations and clinicians in rural practices were at 98 percent and 94 percent, respectively.
CMS is pleased to announce a new funding opportunity for the development, improvement, updating, and expansion of quality measures for use in the Quality Payment Program. CMS will be partnering with clinicians, patients, and other stakeholders to provide up to $30 million of funding and technical assistance in development of quality measures.
CMS is committed to reducing improper payments in all of its programs, as evidenced by improper payment reduction efforts contained in the Fiscal Year 2018 President’s Budget. CMS’ new leadership is re-examining existing corrective actions and exploring new and innovative approaches to reducing improper payments.
We have made great progress in recent years on reforming our system into one that delivers better quality of care for patients and pays for care in a smarter way, including investing more in prevention and primary care. Before 2010, there had been only modest efforts to improve care and reduce costs.